ESR1 and breast cancer: For ER+ breast cancer cell lines, which were sensitive to KAT6 inhibitors, the activity of multiple signaling pathways associated with tumor growth was inhibited, including ER signaling, the cell cycle, and the E2F pathway, as well as luminal transcription factors and coactivators such as ESR1, PGR, E2F, and MYC [180].